Capricor Therapeutics (NASDAQ:CAPR) Announces Quarterly Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15, Zacks reports. The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%.

Capricor Therapeutics Stock Up 5.3 %

CAPR opened at $12.22 on Thursday. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a fifty day moving average of $14.05 and a 200-day moving average of $14.50. The stock has a market cap of $555.64 million, a PE ratio of -11.53 and a beta of 4.10.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.